Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
stomach | 100% | 4011.59 | 359 / 359 | 100% | 140.16 | 286 / 286 |
uterus | 100% | 3309.11 | 170 / 170 | 100% | 127.78 | 459 / 459 |
esophagus | 100% | 6783.06 | 1444 / 1445 | 100% | 139.11 | 183 / 183 |
kidney | 100% | 3942.12 | 89 / 89 | 100% | 88.48 | 900 / 901 |
lung | 100% | 4694.03 | 577 / 578 | 100% | 130.46 | 1155 / 1155 |
prostate | 100% | 4466.55 | 245 / 245 | 100% | 128.19 | 501 / 502 |
skin | 100% | 11690.06 | 1809 / 1809 | 100% | 139.19 | 471 / 472 |
thymus | 100% | 5461.68 | 653 / 653 | 100% | 119.22 | 603 / 605 |
intestine | 100% | 3991.59 | 966 / 966 | 100% | 151.89 | 525 / 527 |
breast | 100% | 5007.02 | 459 / 459 | 99% | 134.22 | 1112 / 1118 |
bladder | 100% | 5036.71 | 21 / 21 | 99% | 183.94 | 501 / 504 |
ovary | 99% | 2070.97 | 178 / 180 | 100% | 127.99 | 430 / 430 |
pancreas | 97% | 2238.86 | 318 / 328 | 100% | 148.15 | 178 / 178 |
brain | 92% | 3681.98 | 2426 / 2642 | 98% | 99.92 | 692 / 705 |
adrenal gland | 100% | 3630.56 | 258 / 258 | 89% | 56.58 | 205 / 230 |
liver | 88% | 1650.62 | 199 / 226 | 99% | 71.82 | 403 / 406 |
adipose | 100% | 5427.24 | 1204 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 73.98 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 93.64 | 29 / 29 |
spleen | 100% | 4260.37 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 119.64 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 181.58 | 1 / 1 |
blood vessel | 100% | 3533.67 | 1329 / 1335 | 0% | 0 | 0 / 0 |
peripheral blood | 96% | 3648.70 | 896 / 929 | 0% | 0 | 0 / 0 |
heart | 94% | 1915.71 | 812 / 861 | 0% | 0 | 0 / 0 |
muscle | 47% | 674.61 | 378 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0035338 | Biological process | long-chain fatty-acyl-CoA biosynthetic process |
GO_0030148 | Biological process | sphingolipid biosynthetic process |
GO_0042761 | Biological process | very long-chain fatty acid biosynthetic process |
GO_0034626 | Biological process | fatty acid elongation, polyunsaturated fatty acid |
GO_0036109 | Biological process | alpha-linolenic acid metabolic process |
GO_0019367 | Biological process | fatty acid elongation, saturated fatty acid |
GO_0006636 | Biological process | unsaturated fatty acid biosynthetic process |
GO_0043651 | Biological process | linoleic acid metabolic process |
GO_0034625 | Biological process | fatty acid elongation, monounsaturated fatty acid |
GO_0061436 | Biological process | establishment of skin barrier |
GO_0046513 | Biological process | ceramide biosynthetic process |
GO_0005783 | Cellular component | endoplasmic reticulum |
GO_0016020 | Cellular component | membrane |
GO_0005789 | Cellular component | endoplasmic reticulum membrane |
GO_0005515 | Molecular function | protein binding |
GO_0009922 | Molecular function | fatty acid elongase activity |
Gene name | ELOVL1 |
Protein name | Very long chain fatty acid elongase 1 (EC 2.3.1.199) (3-keto acyl-CoA synthase ELOVL1) (ELOVL fatty acid elongase 1) (ELOVL FA elongase 1) (Elongation of very long chain fatty acids protein 1) (Very long chain 3-ketoacyl-CoA synthase 1) (Very long chain 3-oxoacyl-CoA synthase 1) Elongation of very long chain fatty acids protein 1 (EC 2.3.1.199) (3-keto acyl-CoA synthase ELOVL1) (ELOVL fatty acid elongase 1) (ELOVL FA elongase 1) (Very long chain 3-ketoacyl-CoA synthase 1) (Very long chain 3-oxoacyl-CoA synthase 1) Elongation of very long chain fatty acids protein (EC 2.3.1.199) (Very-long-chain 3-oxoacyl-CoA synthase) |
Synonyms | SSC1 CGI-88 |
Description | FUNCTION: Catalyzes the first and rate-limiting reaction of the four reactions that constitute the long-chain fatty acids elongation cycle . This endoplasmic reticulum-bound enzymatic process allows the addition of 2 carbons to the chain of long- and very long-chain fatty acids (VLCFAs) per cycle. Condensing enzyme that exhibits activity toward saturated and monounsaturated acyl-CoA substrates, with the highest activity towards C22:0 acyl-CoA. May participate in the production of both saturated and monounsaturated VLCFAs of different chain lengths that are involved in multiple biological processes as precursors of membrane lipids and lipid mediators. Important for saturated C24:0 and monounsaturated C24:1 sphingolipid synthesis . Indirectly inhibits RPE65 via production of VLCFAs. . FUNCTION: Catalyzes the first and rate-limiting reaction of the four reactions that constitute the long-chain fatty acids elongation cycle. This endoplasmic reticulum-bound enzymatic process allows the addition of 2 carbons to the chain of long- and very long-chain fatty acids (VLCFAs) per cycle. Condensing enzyme that exhibits activity toward saturated C18 to C26 acyl-CoA substrates, with the highest activity towards C22:0 acyl-CoA. May participate to the production of both saturated and monounsaturated VLCFAs of different chain lengths that are involved in multiple biological processes as precursors of membrane lipids and lipid mediators. Important for saturated C24:0 and monounsaturated C24:1 sphingolipid synthesis. Indirectly inhibits RPE65 via production of VLCFAs. . |
Accessions | Q502X7 A0A3G2LMN0 ENST00000372458.8 [Q9BW60-1] ENST00000413844.3 [Q9BW60-2] ENST00000621943.4 [Q9BW60-1] Q9BW60 |